Bevacizumab
Bevacizumab
Immunoglobulin G1 (human-mouse monoclonal rhuMAb-VEGF γ-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMAb-VEGF light chain, dimer
Stoffgruppe
Antineoplastisches Mittel (VEGF-Inhibitor)
Halbwertszeit
18-20 Tage